Adamax: The Evidence Card. A Peptide Sold Without a Paper

Adamax is sold as a modified version of Semax, and its mentions in research-peptide communities on Reddit rose from 12 to 48 organic posts between two six-month windows. We searched PubMed, Europe PMC, bioRxiv and medRxiv, CyberLeninka, Google Patents and ClinicalTrials.gov for it; eLibrary.ru refused access. The Russian state register of medicines lists Semax and returns nothing for Adamax. There is no paper, no registered trial and no regulator file describing the molecule, and the one patent text that lists its putative structure neither names nor tests it. What exists is a vendor web page from 2018, a blog post, a Wikipedia entry and a set of product descriptions that do not agree on what the molecule is.

What does anyone actually know about Adamax?

This page asks one question: which statements about Adamax rest on evidence about Adamax itself? To answer it we did three things. We searched the scientific and regulatory record for the molecule under every name and sequence it is sold under. We traced where its structural description comes from. And we checked sixteen claims that circulate about it against the sources that could support or contradict them. The answer is short, and the reasons it matters are not: almost everything said about Adamax is borrowed from other molecules.

Adamax is the clearest current example of a compound whose popularity has grown faster than any documentation of what it is.

What molecule is sold as Adamax?

The description that recurs most often, and the one given by English Wikipedia, is Semax with two changes: an acetyl group on the N-terminus and, on the C-terminus, the 3-aminoadamantane-1-carboxamide residue used in Peptide 021 (P021), a neurotrophic peptide developed at the New York State Institute for Basic Research.^1,2 Written out, that is Ac-Met-Glu-His-Phe-Pro-Gly-Pro-[Ada]-NH2, formula C₅₀H₆₉N₁₁O₁₁S, which we compute at 1,032.2 g/mol. It has no PubChem CID and no CAS number.

That description has no primary source. Wikipedia gives the formula and a SMILES string but cites only a regulator document that names the product without describing it. The earliest verifiable trace of the name is a vendor home page archived on 2 June 2018, which listed “Adamax” in stock.³ A 2021 blog post attributes the compound to that vendor, quotes its description of an “N-acetyl semax base limited at the C-terminus with the adamantyl portion of P21”, and states that the author reconstructed the structure “after reading numerous Reddit threads”.⁴

The notation is also ambiguous. In the P021 literature, “AG” after the sequence denotes a single adamantyl residue. Several product pages write Adamax as Ac-MEHFPGPAG-NH2, and at least one reads “AG” as two ordinary amino acids, alanine and glycine, which describes a different molecule with no adamantane at all.

Table 1. Published structural descriptions of “Adamax”, read on 25 October 2026. Vendors are anonymised on this page; the URLs read, with access date, are listed in the dataset so each observation can be checked. Molecular weights are our calculations from each stated formula or sequence.

One citation error is worth recording because it shows how evidence is borrowed. Vendor A supports its BDNF claim with “Dolotov 2006, PMID 16996040”. That PMID belongs to a paper on the QRFP(26) peptide and energy balance.⁵ The Dolotov paper on Semax and hippocampal BDNF exists, under PMID 16996037,⁶ and it studies Semax, not Adamax.

In plain terms: nobody has published what Adamax is. The common description comes from a seller’s website, and different sellers describe different molecules under the same name.

How much research exists on Adamax?

None that we could locate. We ran the searches below on 25 October 2026; the literal queries and raw results are in the dataset.

Table 2. Census of the scientific and trial record for Adamax. Not consulted, and stated as such: eLibrary.ru (automated access refused; a manual attempt was also refused from outside the CIS). The Russian State Register of Medicines was searched manually for Semax and for Adamax (see Table 3).

0 indexed papers or registered trials describe the molecule sold as Adamax; the one patent text that lists its putative structure neither names nor tests it.

What is known about the molecules it is built from?

Adamax combines pieces of molecules that do have literature. That literature is real, but it describes those molecules, and the next section explains why it cannot be transferred.

• Semax, the parent heptapeptide (an ACTH(4–7) fragment extended with Pro-Gly-Pro), has 210 PubMed records for semax[tiab] (215 when the sequence is added to the query), mostly from Russian groups. It is an authorised medicine in Russia and appears on the Russian list of vital and essential medicines.⁷ The state register lists two current Semax registrations held by INPC Peptogen, LP-No(010596)-(RG-RU) of 18 June 2025 and LP-No(009449)-(RG-RU) of 26 March 2025.¹⁵ In rats it regulates BDNF and TrkB expression in the hippocampus.⁶ We compare it with its sister peptide in Selank vs Semax.
• N-terminally acetylated Semax has at least two papers, identified by reading results rather than by a single bounded query. One shows that acetylation changes how Semax binds copper(II) and zinc(II) and that, unlike free Semax, the acetylated form did not protect neuroblastoma cells from copper toxicity.⁸ The other studies its stability to proteolysis in biological media.⁹
• Peptide 021, the source of the adamantyl residue, has 30–31 records depending on the query (P021[tiab] OR "peptide 021"[tiab]). In mice it was reported to improve learning and memory and to promote neurogenesis.^2,10 P021 is a different peptide, derived from ciliary neurotrophic factor, not from ACTH.
• Adamantane in medicinal chemistry is reviewed as a way to increase lipophilicity and alter metabolism of drug molecules.¹¹ These are general properties of the scaffold, measured in other compounds.

Why can’t Adamax inherit Semax’s evidence?

Because small changes at the ends of this peptide are already known to change what it does. In rats, modifying or replacing the N-terminal methionine of Semax analogues preserved the nootropic-like effect with some substitutions and abolished it with others.¹² Acetylation alone changed metal coordination and removed a protective effect seen with the parent molecule in cells.⁸ Adamax changes both ends at once, and adds a bulky lipophilic group. Whether it binds the same targets, survives in the same media or reaches the same tissues has not been measured.

Shared fragments do not share evidence. Each modification is a new molecule until someone measures it.

In plain terms: Semax has been studied; Adamax has not. Changing even one end of Semax has been shown to change its effects in animals, so results for Semax cannot be assumed for Adamax.

How do regulators treat it?

Table 3. Regulatory status as located on 25 October 2026. “Not named” is not the same as permitted.

In plain terms: one regulator we found, New Zealand’s Medsafe, has proposed classifying peptides of this kind and its committee deferred the decision; no regulator has authorised Adamax, and none has completed an assessment of it in the sources we consulted.

What is claimed, and what supports it?

Selection. The universe is every distinct claim about Adamax’s identity, mechanism, evidence or status found on 25 October 2026 in the top web results for “Adamax peptide” and “Adamax nootropic”, in product pages describing the compound and in the titles and search snippets of the Reddit threads in our count; duplicates were merged. We catalogued sixteen claims that circulate in forums, blogs and product pages, and classified each by the strongest source we could find: primary (evidence about Adamax), by analogy (evidence about Semax, P021 or adamantane), contradicted (a source limits or contradicts it) or no source. Claims about dosing, administration and personal experiences are described only by type, under the research-use-only rule of this site.

Table 4. Claims about Adamax and their strongest source. Of 16 claims: 0 supported by primary evidence, 2 by analogy only (#3, #4), 4 contradicted or partly contradicted (#7–#10), 7 without source (#1, #2, #5, #6, #11, #12, #15; #5 with a related finding pointing the other way) and 3 descriptive or anecdotal (#13, #14, #16).

0 of 16 circulating claims about Adamax are supported by evidence about Adamax itself.

In plain terms: none of the sixteen things commonly said about Adamax is backed by a study of Adamax. The best any of them gets is a study of a related molecule.

How did a compound with no paper become a trend?

The sequence is instructive. The science (Semax in 2006, P021 in 2010, acetylated Semax in 2016) concerns other molecules. The name appears on a vendor site in 2018, is reconstructed by a blog in 2021 (the same year a Ferring patent application lists acetyl-Semax-adamantane as one optional derivative among several),¹⁶ acquires a Wikipedia entry and a regulator mention in 2025, and grows fourfold in organic Reddit posts in 2026. Between our two six-month windows, organic posts rose from 12 to 48, in communities such as r/Biohacking, r/NooTopics and r/Biohackers; posts in vendor-run subreddits were excluded.

How could a laboratory tell the three molecules apart?

Because the three published descriptions are different molecules, a single mass-spectrometry run separates them. We computed, from each stated structure, the exact mass a laboratory would look for and four standard descriptors (Table 5). Every formula was checked against the documented value before any number was used.

Table 5. Computed identity data for the structures sold as Adamax and their comparators. Computed with RDKit 2026.09.1 on 25 October 2026 from SMILES built residue by residue; proton mass 1.007276467 Da. cLogP is the Crippen atom-additive estimate and TPSA the topological polar surface area; both are calculations, not measurements, and are only meaningful for comparing closely related structures. Full SMILES and values in the dataset.

• Mass separates them. The adamantane structure and the Ala-Gly reading differ by 49.06 Da, far outside the error of any routine LC-MS instrument. A certificate that reports a mass of about 1,032 for a product whose label gives the Ala-Gly sequence describes a different molecule from the one on the label.
• One trap. The Ala-Gly amide and the free acid differ by 0.98 Da. A high-resolution instrument separates them easily; at unit resolution the acid falls on the amide’s first carbon-13 isotope peak, only 19 mDa away. Loss of the C-terminal amide also turns the first molecule into the second, so a sample showing the acid’s mass may be a degraded amide rather than acid as supplied. Mass and fragmentation identify the molecule present, not how it got there; a reference standard run under the same conditions, with stability data, does.
• Lipophilicity, by calculation. Adding the adamantyl residue raises the computed cLogP by 1.4 units over acetyl-Semax amide (-0.19 against -1.64). That is consistent with the claim that the group adds lipophilicity. It also raises size and polar surface (1,032 g/mol, 324 Ų, 9 hydrogen-bond donors), and none of these descriptors measures transport across the blood-brain barrier, which for peptides depends on mechanisms such calculations do not capture.

In plain terms: the three “Adamax” molecules weigh different amounts, so a standard lab test can tell which one is in a vial. The adamantane group does make the molecule more fat-loving on paper, but that alone says nothing about whether it reaches the brain.

What does the record allow us to say?

1. Adamax has no documented identity. The common structure is plausible and internally consistent, but no primary source establishes it, and published descriptions disagree (Table 1).
2. Adamax has no research record. No paper or registered trial describes it in the indexes consulted (Table 2). Its putative structure appears once, unnamed and untested, in a 2021 patent application by Ferring BV, three years after the earliest vendor listing.
3. Its claimed properties are borrowed. Every efficacy or mechanism claim rests on Semax, P021 or adamantane chemistry, and modifications of this kind are known to change effects (sections above).
4. A receiving laboratory cannot know which molecule is meant without an independent analytical identity test, because the name refers to at least three described structures. What such a test can and cannot establish is set out in our State of Analytical Evidence study.
5. Regulatory attention has begun in at least one jurisdiction, under the ACTH-analogue category.

It does not allow us to say that Adamax is inactive, unsafe or ineffective. Absence of evidence is the finding; it is not evidence of absence.

What is not known?

• Which structure is actually supplied under the name, measured by mass spectrometry and NMR on independently purchased material.
• Whether the adamantyl cap changes stability in plasma or cerebrospinal-fluid-like media compared with Semax and acetylated Semax.
• Whether the molecule binds the targets proposed for Semax, and whether BDNF and TrkB effects reported for Semax occur at all.
• Whether any regulator besides Medsafe has assessed it, and the outcome of the deferred New Zealand decision.

How to evaluate any “modified” peptide

The same pattern applies to other products sold as upgraded versions of studied peptides. Five questions separate evidence from inheritance:

1. Is there a primary source (paper, patent or analytical report) that defines the exact structure?
2. Does a search under every name and sequence return studies of this molecule, not the parent?
3. Do the cited studies test the modified molecule, or the parent? Check each PMID.
4. Do independent suppliers’ documents describe the same structure, formula and mass, and does the mass on a certificate match the structure on the label (Table 5)?
5. Has any regulator or registry recorded it, and under which category?

What this dossier adds

Against the sources we reviewed (the Wikipedia entry, the 2021 blog, product pages and forum threads), this page adds: a dated, reproducible census across six indexes; the first comparison of the structures published under the name, with computed exact masses, ions and descriptors a laboratory can check a certificate against (Table 5); the documentation of a misattributed citation; the regulator record, including the Medsafe proposal; and a claim-by-claim evidence table.

Methods

Searches were run on 25 October 2026 with literal queries recorded in the dataset: NCBI E-utilities for PubMed, the Europe PMC REST API, bioRxiv/medRxiv search, CyberLeninka, Google Patents and the ClinicalTrials.gov API v2. Every PMID cited here was verified against NCBI on the same date. Structural descriptions were read from public pages and archived; masses were computed from stated formulas or sequences. Reddit counts used posts (not comments) in the six months to 25 October 2026 and the six months before, deduplicated by post ID; posts in vendor-run or synthetic subreddits and homonyms were excluded. The Russian State Register of Medicines (GRLS) was searched manually on 25 October 2026 for Semax and for «Адамакс» and «Adamax», by trade name and by INN, with the CAPTCHA solved by a person; screenshots are archived. Limitations: eLibrary.ru was not consulted (automated and manual access refused, not circumvented); forum threads were assessed from titles and search snippets; Reddit counts are lower bounds. Because the census found no records about the molecule, there was nothing to double-code; the claims table was coded by one editor and checked against the sources a second time. A third coder from a different model family (Codex) then recoded the 16 claims blind: it received only the claim texts and where they circulate, not our sources or verdicts, and searched primary sources itself. Agreement was 10/16 (Cohen’s kappa 0.51). Four of the six disagreements sit on the boundary between “no source” and “by analogy” (#1, #5, #9, #15), where it counted related Semax or patent material as analogy; on #10 it did not locate the Medsafe documents; on #14 it read the patent as supporting the description of Adamax as a chemical hypothesis. Its search found the 2021 patent application that our query had missed, which we have added. No claim moved into “supported by evidence about Adamax” under either coding. An earlier, non-blind recoding agreed on 15 of 16. There is no trials table or human-evidence table because there are no trials or human studies to tabulate (Table 2), and the five figures plot what exists: structures, masses, the empty literature, the timeline and where each claim comes from. The dataset (CC BY 4.0) is available for download.

Declaration of interest

Condor Research sells research peptides, including Semax. Condor Research does not sell Adamax. This dossier was written and funded by Condor Research; every count is reproducible from the published queries.

How to cite

Condor Research Editorial. Adamax: The Evidence Card. A peptide sold without a paper. Version 1.4, 25 October 2026. https://condorresearch.com/research/what-is-adamax/

Changelog. 1.4 (2026-10-25): computed identity data for the three structures (exact masses, ions and descriptors, Table 5). 1.3 (2026-10-25): 2021 Ferring patent application (WO2023046336A1) listing the putative structure added; blind independent recoding replaces the non-blind check; Russian state register searched for Adamax (0 records); search scope stated precisely. 1.2 (2026-10-25): Semax registrations from the Russian state register; independent recoding of the claims; two author figures added (structure blocks, claim provenance). 1.1 (2026-10-25): literal queries and count sensitivity, claim-selection protocol, source links, scoped negatives, claim #5 reclassified, plain-language summaries added. 1.0 (2026-10-25): first version.

Glossary

• Adamantyl group: a rigid, cage-shaped hydrocarbon fragment used in medicinal chemistry to make molecules more lipophilic.
• Acetylation (N-terminal): adding an acetyl group to the first amino acid of a peptide.
• BDNF / TrkB: brain-derived neurotrophic factor and its receptor.
• m/z, monoisotopic mass: what a mass spectrometer reads, mass divided by charge; the monoisotopic mass uses the most abundant isotope of each element.
• cLogP, TPSA: computed estimates of how fat-loving a molecule is and how much of its surface is polar.
• PMID: the unique identifier of a record in PubMed.
• Research use only (RUO): material supplied for laboratory research, not for human or veterinary use.

References

1. Adamax. Wikipedia, revision of 3 May 2026. Accessed 2026-10-25.
2. Li B, Wanka L, Blanchard J, et al. Neurotrophic peptides incorporating adamantane improve learning and memory, promote neurogenesis and synaptic plasticity in mice. FEBS Lett. 2010. PMID 20600002 · doi:10.1016/j.febslet.2010.06.025
3. Vendor home page listing “Adamax”, Internet Archive capture of 2 June 2018. Archived page. Accessed 2026-10-25.
4. Campbell J. Adamax & P21: two new nootropic peptides to watch closely. Blog post, last updated 1 April 2021. Link. Accessed 2026-10-25.
5. Kampe J, et al. Effect of central administration of QRFP(26) peptide on energy balance and characterization of a second QRFP receptor in rat. Brain Res. 2006. PMID 16996040 · doi:10.1016/j.brainres.2006.08.055
6. Dolotov OV, et al. Semax, an analog of ACTH(4-10) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus. Brain Res. 2006. PMID 16996037 · doi:10.1016/j.brainres.2006.07.108
7. Radchenko AI, et al. The potential of the peptide drug Semax and its derivative for correcting pathological impairments in an animal model. Acta Naturae. 2025. PMID 41479572 · doi:10.32607/actanaturae.27808
8. Magrì A, et al. Influence of the N-terminus acetylation of Semax, a synthetic analog of ACTH(4-10), on copper(II) and zinc(II) coordination and biological properties. J Inorg Biochem. 2016. PMID 27586814 · doi:10.1016/j.jinorgbio.2016.08.013
9. Shevchenko KV, et al. Stability of Semax acetyl to proteolysis in various biological media. Dokl Biol Sci. 2013. PMID 23652441 · doi:10.1134/S0012496613020166
10. Bolognin S, et al. Rescue of cognitive-aging by administration of a neurogenic and/or neurotrophic compound. Neurobiol Aging. 2014. PMID 24702821 · doi:10.1016/j.neurobiolaging.2014.02.017
11. Wanka L, Iqbal K, Schreiner PR. The lipophilic bullet hits the targets: medicinal chemistry of adamantane derivatives. Chem Rev. 2013. PMID 23432396 · doi:10.1021/cr100264t
12. Glazova NIu, et al. Effect of modification of the N-terminal region of the molecule on the expression of the neurotropic effect of Semax analogues. Izv Akad Nauk Ser Biol. 2005. PMID 16212268
13. Medsafe (New Zealand Medicines and Medical Devices Safety Authority). Classification of unscheduled peptides. June 2025; and Medicines Classification Committee, minutes of the 74th meeting, 23 July 2025, item 5.7. Proposal · Minutes. Accessed 2026-10-25.
14. Pokrywka A, et al. “Brain doping” substances: prohibited or not in sports? Biol Sport. 2025. PMID 41048238 · doi:10.5114/biolsport.2025.150047
15. State Register of Medicines (GRLS), Ministry of Health of the Russian Federation. Semax: registrations LP-No(010596)-(RG-RU), 18.06.2025, and LP-No(009449)-(RG-RU), 26.03.2025 (record modified 07.07.2025); holder INPC Peptogen JSC. Adamax («Адамакс», «Adamax»): 0 records by trade name and by INN. grls.rosminzdrav.ru. Searched manually 2026-10-25.
16. Vlasenko IV, Merkulova MA (Ferring BV). Adrenocorticotropic hormone peptide compositions and methods of use. WO2023046336A1; priority 22 September 2021, published 30 March 2023. Lists N-acetyl-Met-Glu-His-Phe-Pro-Gly-Pro-adamantane among optional derivatives (description and claims 63-65); examples test only unmodified Semax. Google Patents. Accessed 2026-10-25.

This page describes the scientific and regulatory record of a compound for research and educational purposes. It contains no dosing, administration or usage information and makes no claim of efficacy or safety. Material Condor Research supplies is for laboratory research use only: not for human or veterinary use.